|Dr. Peter M. Hecht||CEO & Director||N/A||N/A||1964|
|Dr. Mark G. Currie||Pres & Chief Scientific Officer||N/A||N/A||1955|
|Mr. William Huyett||Chief Financial Officer||N/A||N/A||1956|
|Mr. Brian M. Cali||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Lawrence Miller||Gen. Counsel||N/A||N/A||N/A|
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its lead product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of serious cardiometabolic diseases, such as diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for serious and orphan central nervous system diseases. The company's products that are in discovery stage include liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.